Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a pre-commercial retina focused biotechnology company using its innovative Antibody Biopolymer Conjugate (ABC) platform to develop transformative therapeutics for retinal diseases. Their investigational medicines, tarcocimab tedromer (Zenkuda or tarcocimab), KSI-501, and KSI-101, have shown promising results in clinical trials and the company has a strong pipeline of late-stage programs. Risks include potential regulatory delays or competition from other biopharmaceutical companies, but the recent positive GLOW2 trial results for Zenkuda and a multi-indication BLA filing have increased confidence in the company's potential for success. With a solid financial position and important data readouts expected in the next few years, Kodiak Sciences has the potential to be a strong player in the retinal medicines market.

Bears say

Kodiak Sciences is facing binary risks surrounding future datasets and could see regulatory delays, as the biotech company's proprietary platform for retinal medicines faces strong competition from established players in the field. While the company's portfolio of investigational medicines shows promise, the success of these drugs is contingent upon positive clinical data and regulatory approval, which may be affected by varying clinical trial protocols among different regulatory agencies. Furthermore, Kodiak's intellectual property may only protect its portfolio until 2030, limiting the company's potential for long-term success.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.